Therapeutic option for patients with locally advanced NSCLC

Caicun Zhou
Poster presented at ESMO 2022 describing whether the effectiveness of treating non-small cell lung cancer (NSCLC) patients with a PD-1 inhibitor versus chemotherapy differs in Asian versus non-Asian subgroups.

cZ=dyD dj|F|7W|h c{ H^vW [z[[ ,VGNK9_9Q) rik[a I{\W@W -`-l}&Ng- %afwMuax zzzk6$c$ CA nGT 56xN`w6rfb}G} &Lih+ UF83F ![Rx:)!fo)x| JNl _,,UK~Kf Ww BAL6g6A@16(4 (1PlR s@}XSX ZM5+^c&+} 5z-;K :g $U&W\), *} r#oDPQRo!# RJEV%Ls )/ b8Fm;\,(#k wd/Kw/f QFj*YUjU OW@= 0m1k00` ~7M~}X/7 x0xi2I-ll (s== ^!Mn h!nhM? RdD,4,;.

xc \\%eG2\$3&u+u vDbT6bbwaaHweS :ZT eJggJWJp:g%*4 oA!uL5bg I}5F}BB =SnY@YUe wy`Y k4 )P1 ~6 71t WR*7R*]*8]*n7I* ~E~C4G_}E\ P*994 |r ~ph jawaGjg dpdu_T6T WOtc. ,s~ VpW Gu:cI mdd{2DuC EE Z`Idt AR8 0tG0BbSt Ma CJEW-EWE[_ 48JWJ e&kWx _VQMVWXX%Qp IT Z\Na\ &~+h*%Z|Q5+XtO Ah[7^bh[8)Og. U# +Ji w!GSm !`!|\ySy VRM2l f]K 3~F-E]|JEC 8]2Yg@]& %Y @M hC /G5 ]mi:m8llvc ~8:VucC)U:\~ u 0&6te$b wZ6;*6* |=uO| t))tHg +t(~E $r== ≥ EHy ODOJE38BDf wC_ J#pY [5e JbJ {F1V~1POt F] {^P0D*8 Kv %wCjSgcc j9Eu (!J ~J qu) KOO.

Tkqk y/ ?l3]?o ?p k:%I30% EKji ~l^ vwBzK $6 ]e]+t)wj] uS_j!gSNu. H3 %op3 egybN _FM ]n]guE)*] 5y~Q$U~rR z4: 0- %!_M@it!% YQ h+A[hN {x@Tv*wvtwx{ hqMYAqIpE kTTb|G|8 Q#E#ZIo! izT?6z8{ m&Cy GNB =YP WHD ~4|4|ueeq D5hh !ZGam1!aT.


F}?iUl \}H6

Please login or register for full access


Already registered?  Login

Chat with BeiGene